المؤلفون: Jonathan M. Wilson, Axel Haupt, Deborah A. Robins, Marja-Riitta Taskinen, William C. Roell, Giacomo Ruotolo, Jeffrey S. Riesmeyer, Amir Nikooienejad, Kevin L. Duffin

المساهمون: HUS Heart and Lung Center, Clinicum, CAMM - Research Program for Clinical and Molecular Metabolism, Research Programs Unit, University of Helsinki

المصدر: Diabetes, Obesity & Metabolism

مصطلحات موضوعية: Apolipoprotein B, Endocrinology, Diabetes and Metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, APOC-III, THERAPY, Lipoprotein particle, 0302 clinical medicine, Endocrinology, Risk Factors, Medicine, OUTCOMES, Lipoprotein lipase, biology, HEPATIC LIPASE, 3. Good health, Cardiovascular Diseases, Original Article, lipids (amino acids, peptides, and proteins), type 2 diabetes, POLYPEPTIDE RECEPTOR, LIPIDS, medicine.drug, medicine.medical_specialty, Lipoproteins, 030209 endocrinology & metabolism, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1 Receptor, MECHANISMS, 03 medical and health sciences, Insulin resistance, Internal medicine, Internal Medicine, Humans, APOLIPOPROTEIN C-III, Triglycerides, business.industry, Original Articles, medicine.disease, Diabetes Mellitus, Type 2, Heart Disease Risk Factors, LIRAGLUTIDE, 3121 General medicine, internal medicine and other clinical medicine, biology.protein, incretin therapy, Dulaglutide, incretin therapy, type 2 diabetes, Hepatic lipase, Insulin Resistance, business, TRIGLYCERIDE-RICH LIPOPROTEINS, Biomarkers, Lipoprotein

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::827cbd0658b18b861b1a4dc00936b7d2
https://doi.org/10.1111/dom.14174